Similar articles

• Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.

  Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gómez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C. Smith MR, et al. Lancet. 2012 Jan 7;379(9810):39-46. doi: 10.1016/S0140-6736(11)61226-9. Epub 2011 Nov 15. Lancet. 2012. PMID: 22093187 Free PMC article. Clinical Trial.
• A comprehensive review of denosumab for bone metastasis in patients with solid tumors.

  Gül G, Sendur MA, Aksoy S, Sever AR, Altundag K. Gül G, et al. Curr Med Res Opin. 2016;32(1):133-45. doi: 10.1185/03007995.2015.1105795. Epub 2015 Nov 25. Curr Med Res Opin. 2016. PMID: 26451465 Review.
• [The clinical merit of anti-RANKL antibody denosumab in prostate cancer].

  Akaza H, Tsukamoto T, Suzuki K, Namiki M, Ozono S, Naitodept S. Akaza H, et al. Gan To Kagaku Ryoho. 2012 Feb;39(2):207-12. Gan To Kagaku Ryoho. 2012. PMID: 22333629 Japanese.
• Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer?

  Saylor PJ, Michaelson MD. Saylor PJ, et al. Oncologist. 2012;17(2):288-90. doi: 10.1634/theoncologist.2011-0433. Epub 2012 Jan 20. Oncologist. 2012. PMID: 22267850 Free PMC article.
• Management of bone metastases in refractory prostate cancer--role of denosumab.

  Paller CJ, Carducci MA, Philips GK. Paller CJ, et al. Clin Interv Aging. 2012;7:363-72. doi: 10.2147/CIA.S27930. Epub 2012 Sep 17. Clin Interv Aging. 2012. PMID: 23049248 Free PMC article. Review.